Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y. Chiwata M, et al. Among authors: kawaguchi y. Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22. Intern Med. 2021. PMID: 33612681 Free PMC article.
Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Matsuo E, Miyazaki Y, Tsutsumi C, Inoue Y, Yamasaki R, Hata T, Fukushima T, Tsushima H, Imanishi D, Imaizumi Y, Iwanaga M, Sakai M, Ando K, Sawayama Y, Ogawa D, Kawaguchi Y, Nagai K, Tsukasaki K, Ikeda S, Moriuchi Y, Yoshida S, Honda M, Taguchi J, Onimaru Y, Tsuchiya T, Tawara M, Atogami S, Yamamura M, Soda H, Yoshida Y, Matsuo Y, Nonaka H, Joh T, Takasaki Y, Kawasaki C, Momita S, Jinnai I, Kuriyama K, Tomonaga M. Matsuo E, et al. Among authors: kawaguchi y. Int J Hematol. 2007 Feb;85(2):132-9. doi: 10.1532/IJH97.06157. Int J Hematol. 2007. PMID: 17321991 Clinical Trial.
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group.
Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T, Imaizumi Y, Imanishi D, Taguchi J, Iwanaga M, Tsushima H, Inoue Y, Takasaki Y, Tsuchiya T, Komoda M, Ando K, Horio K, Moriwaki Y, Tominaga S, Itonaga H, Nagai K, Tsukasaki K, Tsutsumi C, Sawayama Y, Yamasaki R, Ogawa D, Kawaguchi Y, Ikeda S, Yoshida S, Onimaru Y, Tawara M, Atogami S, Koida S, Joh T, Yamamura M, Matsuo Y, Soda H, Nonaka H, Jinnai I, Kuriyama K, Tomonaga M. Sakai M, et al. Among authors: kawaguchi y. Int J Hematol. 2009 Apr;89(3):319-325. doi: 10.1007/s12185-009-0263-z. Epub 2009 Mar 6. Int J Hematol. 2009. PMID: 19266256
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. Itonaga H, et al. Among authors: kawaguchi y. Int J Hematol. 2012 Feb;95(2):209-13. doi: 10.1007/s12185-012-1005-1. Epub 2012 Jan 20. Int J Hematol. 2012. PMID: 22262141 Free article.
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y. Itonaga H, et al. Among authors: kawaguchi y. Leuk Res. 2014 Jan;38(1):76-83. doi: 10.1016/j.leukres.2013.10.022. Epub 2013 Nov 5. Leuk Res. 2014. PMID: 24262285 Free article.
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E, Hata T, Yokota KI, Chiwata M, Kamijo R, Hashimoto M, Taguchi M, Horai M, Matsuo M, Matsuo E, Takasaki Y, Kawaguchi Y, Itonaga H, Sato S, Ando K, Sawayama Y, Taguchi J, Imaizumi Y, Tsushima H, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y. Toriyama E, et al. Among authors: kawaguchi y. Cancer Sci. 2020 Dec;111(12):4490-4499. doi: 10.1111/cas.14653. Epub 2020 Oct 23. Cancer Sci. 2020. PMID: 32939867 Free PMC article.
Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki.
Matsuo M, Iwanaga M, Kondo H, Soda M, Jo T, Horio K, Takasaki Y, Kawaguchi Y, Tsushima H, Imaizumi Y, Imanishi D, Taguchi J, Sawayama Y, Hata T, Miyazaki Y. Matsuo M, et al. Among authors: kawaguchi y. Cancer Sci. 2016 Oct;107(10):1484-1491. doi: 10.1111/cas.13025. Epub 2016 Sep 2. Cancer Sci. 2016. PMID: 27487572 Free PMC article.
Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki.
Horai M, Satoh S, Matsuo M, Iwanaga M, Horio K, Jo T, Takasaki Y, Kawaguchi Y, Tsushima H, Yoshida S, Taguchi M, Itonaga H, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Moriuchi Y, Haase D, Yoshiura KI, Miyazaki Y. Horai M, et al. Among authors: kawaguchi y. Br J Haematol. 2018 Feb;180(3):381-390. doi: 10.1111/bjh.15050. Epub 2017 Dec 19. Br J Haematol. 2018. PMID: 29265181 Free article.
2,677 results